SINO BIOPHARMACEUTICAL
Sino Biopharmaceutical engages in pharmaceutical products which covers an array of R&D platforms, a line-up of intelligent production and a strong sales system. The Group's products have gained a competitive foothold in various therapeutic categories with promising potentials, comprising a variety of biopharmaceutical and chemical medicines for treating tumours, liver diseases, cardio-cerebral diseases, analgesia, respiratory system diseases and orthopedicdiseases.
SINO BIOPHARMACEUTICAL
Industry:
Biotechnology Health Care Health Diagnostics Hospital Medical Pharmaceutical
Founded:
1997-02-02
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Nginx Euro Google Apps For Business Pound Sterling Japanese Yen Java EE Network Solutions DNS Unsplash
Similar Organizations
Celator Pharmaceuticals
Celator Pharmaceuticals is a biopharmaceutical company developing therapies to treat cancer, using the drug ratio technology platform.
Fatigue Science Institute
Fatigue Science is a research, development and sales of medical technology and medical supplies for various diseases, and treatment.
Kanzawa Medical Research Foundation
Kanzawa Medical Research Foundation promotes the development of healthcare and medical science by encouraging studies.
Samjin Pharmaceutical
Samjin Pharmaceutical is a company that pioneeres a healthy life for human beings with a creative mind and advances for a prosperous future.
Current Employees Featured
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-03-23 | Softhale | Softhale acquired by Sino Biopharmaceutical | 110 M USD |
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2022-06-02 | Generon (Shanghai) Corporation | Sino Biopharmaceutical investment in Venture Round - Generon (Shanghai) Corporation | 70 M USD |
| 2021-12-12 | Medlinker | Sino Biopharmaceutical investment in Series E - Medlinker | 514 M USD |
| 2021-11-18 | Treadwell Therapeutics | Sino Biopharmaceutical investment in Series B - Treadwell Therapeutics | 91 M USD |
| 2021-08-11 | XtalPi | Sino Biopharmaceutical investment in Series D - XtalPi | 400 M USD |
| 2020-12-06 | Sinovac Life Sciences | Sino Biopharmaceutical investment in Corporate Round - Sinovac Life Sciences | 500 M USD |
| 2019-11-04 | Akeso Biopharma | Sino Biopharmaceutical investment in Series D - Akeso Biopharma | 150 M USD |
| 2015-08-05 | LifeBond | Sino Biopharmaceutical investment in Series D - LifeBond | 27 M USD |
More informations about "Sino Biopharmaceutical"
Sino Biopharmaceutical Limited - Wikipedia
Sino Biopharmaceutical Limited (SEHK: 1177 | Hang Seng Index component) (simplified Chinese: 中国生物制药有限公司; traditional Chinese: 中國生物製藥有限公司), shortly Sino Biopharm, …See details»
Sino Biopharmaceutical Ltd. - Drug pipelines, Patents, Clinical trials ...
May 7, 2025 Explore Sino Biopharmaceutical Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 135 news, and 445 literature, Disease Domain:Neoplasms, …See details»
Sino Biopharmaceutical | World Economic Forum
Sino Biopharmaceutical is a leading pharmaceutical conglomerate in China, specializing in biopharmaceutical and chemical medicines. Listed on the Hong Kong Stock Exchange since …See details»
Sino Biopharmaceutical - Crunchbase Company Profile …
Sino Biopharmaceutical is a pharmaceutical company that engages in research, development and pharmaceutical products for treating diseases.See details»
Sino Biopharmaceutical - Pharmaceutical Companies Database
Sino Biopharmaceutical Limited and its subsidiaries are the leading innovative research and R&D-driven pharmaceutical group in China, with a business scope that covers the full industry chain …See details»
Sino Biopharmaceutical 2025 Company Profile: Stock …
Information on stock, financials, earnings, subsidiaries, investors, and executives for Sino Biopharmaceutical. Use the PitchBook Platform to explore the full profile.See details»
Sino Biopharmaceutical - businessabc
Jun 29, 2025 Sino Biopharmaceutical was established in 1979 in Hong Kong and was one of the earlier pharmaceutical companies in the China region. In recent years, the company has …See details»
Sino Biopharmaceutical (HKG:1177) Company Profile & Description
5 days ago Company profile for Sino Biopharmaceutical Limited (HKG:1177) with a description, list of executives, contact details and other key facts.See details»
Presentation - Sino Biopharm
About Us About Sino Biopharm Board of Directors Senior Management R&D R&D Team Products Product List Sustainability ESG Governance ESG Management Practices …See details»
Sino Biopharmaceutical - Drug Discovery and Development
Sino Biopharmaceutical achieved strong financial results in 2024, with revenue reaching RMB 28.87B ($4.0B), a 10.2% YoY increase. Profit rose by 24.9% to RMB 6.36B, while profit …See details»
SINO BIOPHARMACEUTICAL LIMITED - hkexnews.hk
Sino Biopharmaceutical Limited (the “Company” or “Sino Biopharm”, together with its subsidiaries, the “Group”) is a leading, innovative R&D-driven pharmaceutical conglomerate in China. It …See details»
Sino Biopharmaceutical | 世界经济论坛
Sino Biopharmaceutical is a leading pharmaceutical conglomerate in China, specializing in biopharmaceutical and chemical medicines. Listed on the Hong Kong Stock Exchange since …See details»
Sino Biopharmaceutical, One of the Largest Chinese ... - Morningstar
Aug 14, 2024 Sino Biopharmaceutical was initially anchored in hepatitis medicines with its flagship drug Tianqing Ganmei, which was approved in 2005 in China. Since the introduction …See details»
Sino Biopharmaceutical Limited - Wikiwand
Sino Biopharmaceutical Limited (SEHK: 1177 | Hang Seng Index component) (simplified Chinese:中国生物制药有限公司; traditional Chinese:中國生物製藥有限公司), shortly Sino …See details»
Sino Biopharm to Buy Out LaNova for Up to USD951 Million, …
1 day ago (Yicai) July 17 -- Sino Biopharmaceutical said it plans to spend as much as USD951 million to fully acquire LaNova Medicines, a move that may point to more mergers and …See details»
Sino Biopharm - 中国生物制药：健康科技，温暖更多生命
6月25日，2025年“夏季达沃斯论坛”在天津举行。国务院总理李强出席论坛开幕式与工商界代表座谈会。See details»
Sino Biopharm to Fully Acquire LaNova in $951M Oncology Deal
2 days ago Sino Biopharmaceutical is acquiring the remaining stake in LaNova Medicines for US $950.9 million to bolster its cancer drug pipeline, integrating LaNova’s innovative antibody …See details»
About Us - Sino Biopharm
The company's subordinate enterprises are located in Beijing, Shanghai, Nanjing, Lianyungang, Qingdao and other places, and have multiple manufacturing sites. CTTQ is the largest …See details»
Sino Biopharmaceutical to acquire LaNova Medicines for up to …
3 days ago Hong Kong-listed Sino Biopharmaceutical said on Tuesday it will buy the remaining 95.09% stake it does not hold in Shanghai-based LaNova Medicines for no more than $950.92 …See details»
Sino Biopharma spends $951m to acquire China-based LaNova …
3 days ago Hong Kong-listed Sino Biopharmaceutical will acquire China-based oncology specialist LaNova Medicines in a deal that will not exceed $951m, representing one of the …See details»